Patents Examined by Lia E Taylor
-
Patent number: 11643466Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.Type: GrantFiled: August 19, 2021Date of Patent: May 9, 2023Assignee: QLSF BIOTHERAPEUTICS INC.Inventor: Shihao Chen
-
Patent number: 11629198Abstract: Compositions and methods are provided for loading cargoes onto red blood cells. Provided herein are novel antibodies, fragments, fusion proteins and other conjugates which specifically bind red blood cells via RHCE or Band 3.Type: GrantFiled: December 5, 2018Date of Patent: April 18, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Carlos H. Villa, Vladimir R. Muzykantov, Donald L. Siegel, Colin Greineder
-
Patent number: 11623954Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.Type: GrantFiled: July 9, 2018Date of Patent: April 11, 2023Assignee: INNATE PHARMAInventors: Stéphanie Cornen, Benjamin Rossi, Nicolai Wagtmann, Laurent Gauthier
-
Patent number: 11623949Abstract: The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.Type: GrantFiled: January 27, 2022Date of Patent: April 11, 2023Assignee: Talem Therapeutics LLCInventors: Ilse Roodink, Yasmina Noubia Abdiche, Jennifer L. Bath
-
Patent number: 11603405Abstract: The present invention relates to antibodies that specifically bind CD3. The present invention relates to antibodies that specifically bind PSMA. The present invention relates to antibodies that specifically bind CD3 and PSMA. The present invention relates to antibodies that specifically bind IL1RAP. The present invention relates to antibodies that specifically bind CD33. The present invention relates to antibodies that specifically bind CD3 and IL1RAP. The present invention relates to antibodies that specifically bind CD3 and CD33. The present invention relates to antibodies that specifically bind TMEFF2. The present invention relates to antibodies that specifically bind CD3 and TMEFF2. The present invention relates to fragments of the antibodies, polynucleotides encoding the antibodies or fragments thereof, and methods of making and using the same.Type: GrantFiled: May 21, 2019Date of Patent: March 14, 2023Assignee: JANSSEN BIOTECH, INC.Inventors: Francois Gaudet, Jill Giles-Komar, Bradley Heidrich, Chichi Huang, Colleen Kane, Ronan McDaid, Jennifer Nemeth-Seay
-
Patent number: 11591399Abstract: The present invention relates to anti-human PD-L2 antibodies, or the antigen binding parts thereof, which specifically bind human PD-L2 such that PD-L2 binding to PD-1 is blocked, wherein preferably said antibodies or antigen binding parts do not bind to mouse PD-L2 and human PD-L1 but bind to cyno PD-L2, preferably as determined by FACS analysis. The present invention also relates to nucleotide sequences encoding the anti-human PD-L2 antibodies, vectors and cells containing the nucleotide sequences. The antibodies and/or compositions of the invention are useful in human therapy, e.g., cancer therapy, and/or in cell-line based bioassays for determining T cell signalling.Type: GrantFiled: February 14, 2019Date of Patent: February 28, 2023Assignee: ABBA THERAPEUTICS AGInventors: Reto Simon Kohler, Gongda Xue, Lena Cron
-
Patent number: 11583568Abstract: The present disclosure relates to the use of angiotensin II, angiotensin III, or angiotensin IV in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.Type: GrantFiled: April 13, 2018Date of Patent: February 21, 2023Assignee: La Jolla Pharma, LLCInventors: Lakhmir Chawla, George Tidmarsh, Steve Ching Tsung Chen
-
Patent number: 11542329Abstract: The present disclosure provides antibodies or antibody fragments specific for GPVI. In particular, it relates to antibodies or antibody fragments that have combined beneficial properties and are therefore useful for the treatment or prophylaxis of GPVI related disorders or conditions, such as for example thrombotic or vascular disorders.Type: GrantFiled: May 15, 2019Date of Patent: January 3, 2023Assignee: Morphosys AGInventors: Kerstin Uhland, Julia Neugebauer, Steffen Runz
-
Patent number: 11542486Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.Type: GrantFiled: March 2, 2017Date of Patent: January 3, 2023Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: George Georgiou, Everett Stone, John Blazeck
-
Patent number: 11498960Abstract: The disclosure provides engineered polypeptides that specifically bind to human complement component C5 and/or serum albumin. The disclosure also provides fusion proteins comprising such engineered polypeptides, wherein such fusion proteins may be multivalent and multi-specific fusion proteins. The disclosure further provides nucleic acid molecules that encode such engineered polypeptides or fusion proteins, and methods of making such engineered polypeptides or fusion proteins. The disclosure further provides pharmaceutical compositions that comprise such engineered polypeptides or fusion proteins, and methods of treatment using such engineered polypeptides or fusion proteins.Type: GrantFiled: July 11, 2018Date of Patent: November 15, 2022Assignee: Alexion Pharmaceuticals, Inc.Inventors: Bridget Puffer, Julian Chandler, Nimish Gera, Douglas L. Sheridan, Siddharth Jindal, Paul P. Tamburini
-
Patent number: 11492391Abstract: Infection with obligatory intracellular bacteria is difficult to treat as intracellular targets and delivery methods of therapeutics are not well-known. Ehrlichia translocated factor-1 (Etf-1), a type IV secretion system (T4SS) effector, is a primary virulence factor for an obligatory intracellular bacterium, Ehrlichia chaffeensis. Disclosed herein are Etf-1-specific nanobodies (Nbs) that block Etf-1 functions and Ehrlichia infection. Also disclosed is a method for treating human monocytic ehrlichiosis (HME) in a subject with the disclosed nanobodies.Type: GrantFiled: March 14, 2022Date of Patent: November 8, 2022Assignee: Ohio State Innovation FoundationInventors: Yasuko Rikihisa, Wenqing Zhang
-
Patent number: 11485775Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.Type: GrantFiled: October 20, 2017Date of Patent: November 1, 2022Assignee: Adimab, LLCInventor: Laura M. Walker
-
Patent number: 11485768Abstract: The invention relates to isolated immunogenic peptides comprising a CD1d binding peptide, and immediately adjacent or separated from said CD1d binding peptide, a redox motif sequence which is further flanked by a histidine or tryptophan amino acids. The invention further relates to these peptides for use as a medicament The invention further relates to methods wherein these peptides are used for generating NKT cells which are cytolytic against cells presenting the cognate antigen.Type: GrantFiled: April 19, 2017Date of Patent: November 1, 2022Assignee: IMCYSE SAInventor: Luc Vander Elst
-
Patent number: 11466084Abstract: The application provides anti-PD-1 monoclonal antibodies, antigen binding portions thereof, therapeutic compositions thereof and/or nucleic acid encoding the same, and their use to upregulate the function of T-cells to enhance cell-mediated immune responses in the treatment of cancer and other T-cell dysfunctional disorders.Type: GrantFiled: June 22, 2018Date of Patent: October 11, 2022Assignee: SYSTIMMUNE, INC.Inventors: Brian Kovacevich, Dong Xia, Anne E. Jensen, Jonathan K. Fallen, Blair Renshaw, Jeffrey B. Adamo, Phil Tan, Zeren Gao, Yi Zhu
-
Patent number: 11459385Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.Type: GrantFiled: July 9, 2020Date of Patent: October 4, 2022Assignees: The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University, Pfizer, Inc.Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
-
Patent number: 11434282Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.Type: GrantFiled: June 17, 2021Date of Patent: September 6, 2022Assignees: Chan Zuckerberg Biohub, Inc., The Board of Trustees of the Leland Stanford Junior UniversityInventors: Derek Croote, Stephen R. Quake, Kari Nadeau, Spyros Darmanis, David N. Cornfield
-
Patent number: 11401329Abstract: Anti-CD47 antibodies and antigen-binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, and methods of producing the antibodies and using the antibodies for treating or preventing diseases such as cancer, inflammatory disease, infectious disease, atherosclerosis, cardiovascular disease, metabolic disease, radiation-induced injury, and/or autoimmune disease.Type: GrantFiled: July 30, 2018Date of Patent: August 2, 2022Assignee: Phanes Therapeutics, Inc.Inventors: Minghan Wang, Hui Zou, Joshua Oaks, Haiqun Jia
-
Patent number: 11401324Abstract: Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.Type: GrantFiled: August 29, 2019Date of Patent: August 2, 2022Assignee: HCW Biologics, Inc.Inventor: Hing Wong
-
Patent number: 11359010Abstract: It is provided an inhibitor of Toll-like Receptor 2 (TLR2) that specifically blocks an interaction between S1009A and Toll-like Receptor 2 (TLR2), and more particularly a humanized antibody against S100A9 protein for inhibiting and treating inflammatory conditions in a human patient. Particularly, this humanized antibody is specific for blocking the interaction between the S100A9 protein and the TLR-2 receptor.Type: GrantFiled: July 11, 2016Date of Patent: June 14, 2022Assignee: UNIVERSITÉ LAVALInventors: Philippe Tessier, Mélanie Tardif, Traian Sulea
-
Patent number: 11359011Abstract: The methods and compositions described herein improve cardiovascular outcomes using measures related to systemic chronic inflammation (the inflammatory age—iAge, the cardiovascular age—cAge, and levels of certain markers) to stratify patients into low risk and high risk groups. The personalized immune proteome signature creates an individualized initial therapy to reduce cAge and to convert high risk patients into low risk patients. High risk patients can be converted to low risk patients by treating the patients to reduce their cAge, iAge and/or improve their CRS.Type: GrantFiled: August 6, 2020Date of Patent: June 14, 2022Assignee: Edifice Health, Inc.Inventor: David Furman